Scarica l'app Stockscreener
26.86
4.04%
-1.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$27.99
Aprire:
$27.77
Volume 24 ore:
1.21M
Relative Volume:
0.70
Capitalizzazione di mercato:
$3.36B
Reddito:
$415.62M
Utile/perdita netta:
$-2.38M
Rapporto P/E:
-945.77
EPS:
-0.0284
Flusso di cassa netto:
$16.92M
1 W Prestazione:
-1.79%
1M Prestazione:
+2.44%
6M Prestazione:
+5.87%
1 anno Prestazione:
+84.22%
Intervallo 1D:
$26.32
$27.96
Intervallo di 1 settimana:
$26.32
$28.60
Portata 52W:
$13.70
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
26.86 | 3.48B | 415.62M | -2.38M | 16.92M | -0.0284 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Arcutis Biotherapeutics (ARQT) Stock Analysis: Riding High On A 24% Potential Upside - DirectorsTalk Interviews
ARQT|Arcutis Biotherapeutics Inc|Price:27.860|Chg%:+0.510 - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Balance Sheet - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Cash Flow - TradingKey
Arcutis Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:ARQT - TradingView
Arcutis Biotherapeutics Inc (ARQT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arcutis: Intense Competition, Costs, Slow Growth Merit Downgrade To Hold (NASDAQ:ARQT) - Seeking Alpha
Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup - ChartMill
Enterprise value to revenue forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
Understanding Momentum Shifts in (ARQT) - Stock Traders Daily
META_TITLE_QUOTE - Yahoo Finance
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a Bet - Yahoo Finance
The Bull Case For Arcutis Biotherapeutics (ARQT) Could Change Following FDA Acceptance Of Infant ZORYVE sNDA - webull.com
Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum - ChartMill
Guggenheim Remains a Buy on Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Arcutis Biotherapeutics director Howard G. Welgus disposes of 4,730 common shares worth $127,269.30 - Bitget
Arcutis Biotherapeutics director sells $127,284 in stock - Investing.com UK
Form 4 Arcutis Biotherapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics (ARQT) director receives RSUs and stock options - Stock Titan
Arcutis Biotherapeutics director sells $127,284 in stock By Investing.com - Investing.com UK
Arcutis Biotherapeutics (ARQT) director trades stock under 10b5-1 plan - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup - ChartMill
Arcutis Biotherapeutics Appoints Chris Peetz to Board of Directors to Drive Growth and Innovation in Immuno-Dermatology 1 – Minichart - Minichart
Arcutis Biotherapeutics Enhances Board Governance with Christopher Peetz Joining as Tenth Director - Kalkine Media
Arcutis Biotherapeutics appoints Chris Peetz to board By Investing.com - Investing.com South Africa
Arcutis appoints Christopher Peetz to its board as Class III director - TradingView
Arcutis Biotherapeutics (Nasdaq: ARQT) names Chris Peetz to its board - Stock Titan
Arcutis Biotherapeutics, Inc. Appoints Christopher Peetz to its Board of Directors, Effective July 15, 2026 - marketscreener.com
Arcutis Biotherapeutics appoints Chris Peetz to board - Investing.com
Arcutis appoints Chris Peetz to its Board to bo... - Pluang
Arcutis Expands Board of Directors with Appointment of Chris Peetz - The Manila Times
Press Release: Arcutis Expands Board of Directors With Appointment of Chris Peetz - Moomoo
Attovia Therapeutics appoints John Smither to board By Investing.com - Investing.com Australia
Arcutis to report Q2 2026 financial results on August 5 - scanx.trade
Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 - The Manila Times
Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 4730 common shares - Stock Titan
Arcutis schedules Aug. 5 webcast for its business update - Stock Titan
FDA accepts Arcutis application for infant eczema treatment By Investing.com - Investing.com Nigeria
Arcutis gets FDA review for Zoryve 0.05% label expansion - MSN
Arcutis Biotherapeutics (ARQT) Receives a Buy from Jefferies - The Globe and Mail
Could Arcutis (ARQT) Infant Label Bid Clarify the Limits of Its Single-Drug Strategy? - simplywall.st
BREAKING: US FDA Sets PDUFA for Roflumilast Cream 0.05% in Infants With AD - The Dermatology Digest
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis gets FDA review for Zoryve 0.05% label expansion (ARQT) - Seeking Alpha
Arcutis Biotherapeutics (ARQT) Receives FDA Acceptance for Zoryve Cream - GuruFocus
FDA accepts Arcutis application for infant eczema treatment - Investing.com
Arcutis: FDA to Review Zoryve for Atopic Dermatitis in Infants - Moomoo
FDA accepts Arcutis' application to expand ZORY... - Pluang
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - The Manila Times
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arcutis Biotherapeutics Inc Azioni (ARQT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Welgus Howard G. | Director |
Jul 15 '26 |
Sale |
26.91 |
4,730 |
127,284 |
37,109 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):